

Sponsored by:
Stanford University Cancer Institute,
UC Davis Comprehensive Cancer Center, and
UCSF Helen Diller Family Comprehensive Cancer Center
The Association of Northern California Oncologists,

24th Multidisciplinary Management of Cancers: A Case-based Approach

March 15-17, 2024
Hybrid

Course Co-Directors
A. Dimitrios Colevas, MD
David Gandara, MD
Margaret Tempero, MD



Table of Contents

Contents

EXHIBITOR LIST	3
COURSE OVERVIEW	4
Learning Objectives	4
Accreditation	4
GENERAL INFORMATION	6
FACULTY LIST	9
Conference Course Directors	9
Panel Chairs	9
Panelists	10
DISCLOSURES	15
COURSE PROGRAM	16

EXHIBITOR LIST

AbbVie
ADC Therapeutics
Alexion Pharmaceuticals
Amgen
Apellis Pharmaceuticals, Inc.
AstraZeneca
Aveo Oncology, an LG Chem Company
BeiGene USA, Inc.
Bristol-Myers Squibb Oncology
Cancer Support Community
Coherus BioSciences
Daiichi Sankyo, Inc.
EMD Serono
Exact Sciences
Exelixis, Inc.
Genentech Inc., a Member of the Roche Group
Genmab
Gilead Sciences, Inc.
GSK Oncology
Guardant Health
Incyte Corporation
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Johnson & Johnson
Kite, A Gilead Company
Lilly Oncology
Merck & Co., Inc.
Mirati Therapeutics
Novartis Pharmaceuticals
Pharma Essentia USA Corporation
Pharmacyclics LLC, an AbbVie Company
Puma Biotechnology, Inc.
Regeneron
Sanofi Genzyme
Seagen
Servier Pharmaceuticals
Sobi
SpringWorks Therapeutics
Stanford Cancer Institute
Stemline, A Menarini Group Company
Sumitomo Pharma America, Inc.
Taiho Oncology Inc.
Takeda Oncology
TerSera Therapeutics
Thesecondopinion
UCSF Helen Diller Faily Comprehensive Cancer Centre

COURSE OVERVIEW

Learning Objectives

Upon completion of this program, attendees will be able to:

- Develop multidisciplinary treatment strategies based on national clinical practice guidelines in oncology to improve quality of care for cancer patients
- Counsel patients on pharmacological and psychiatric strategies to manage pain
- Discuss relevant clinical trials with cancer patients and refer appropriately
- Appropriately refer cancer patients to palliative care

Accreditation

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

i3 Health designates this live activity for a maximum of 15.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME. Physician assistants may receive a maximum of 15.0 hours of Category 1 credit for completing this program.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts 15.0 *AMA PRA Category 1 Credits*[™] from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

REQUIREMENTS FOR CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity. Your certificate of attendance will be mailed or emailed to you in approximately 2 weeks.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

MOC Recognition Statement (for MOC activities)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.0 Medical Knowledge MOC points in the American Board of Internal

Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Faculty Disclosure Declaration

i3 Health and ANCO endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health and ANCO will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and ANCO do not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners and managers have nothing to disclose. -The Association of Northern California Oncologists planners and managers have nothing to disclose.

i3 Health and ANCO have mitigated all relevant financial relationships. See list of Disclosures in Appendix

GENERAL INFORMATION

Attendance Verification/Sign-In Sheet / CME Certificates

After the meeting, if you elected to claim credits, you will receive an email from mmc2024-registration@icsevents.com with a link to complete your online **Course Evaluation**. CME certificates will be sent out by I3 Health, approximately 2 weeks post conference. Please make sure that you add this email to your safe senders list.

Session Survey

Your opinion is important to us – we do listen! The session survey will be available after each session.

Exhibits

Industry exhibits will be available during the conference in the Royal Oak and Fairway Deck Rooms.

Federal and State Law

Regarding Linguistic Access and Services for Limited English Proficient Persons

I. Purpose.

This document is intended to satisfy the requirements set forth in California Business and Professions code 2190.1. California law requires physicians to obtain training in cultural and linguistic competency as part of their continuing medical education programs. This document and the attachments are intended to provide physicians with an overview of federal and state laws regarding linguistic access and services for limited English proficient (“LEP”) persons. Other federal and state laws not reviewed below also may govern the manner in which physicians and healthcare providers render services for disabled, hearing impaired or other protected categories

II. Federal Law – Federal Civil Rights Act of 1964, Executive Order 13166, August 11, 2000, and Department of Health and Human Services (“HHS”) Regulations and LEP Guidance.

The Federal Civil Rights Act of 1964, as amended, and HHS regulations require recipients of federal financial assistance (“Recipients”) to take reasonable steps to ensure that LEP persons have meaningful access to federally funded programs and services. Failure to provide LEP individuals with access to federally funded programs and services may constitute national origin discrimination, which may be remedied by federal agency enforcement action. Recipients may include physicians, hospitals, universities and academic medical centers who receive grants, training, equipment, surplus property and other assistance from the federal government.

HHS recently issued revised guidance documents for Recipients to ensure that they understand their obligations to provide language assistance services to LEP persons. A copy of HHS’s summary document entitled “Guidance for Federal Financial Assistance Recipients Regarding Title VI and the Prohibition Against National Origin Discrimination Affecting Limited English Proficient Persons – Summary” is available at HHS’s website at: <http://www.hhs.gov/ocr/lep/>.

As noted above, Recipients generally must provide meaningful access to their programs and services for LEP persons. The rule, however, is a flexible one and HHS recognizes that “reasonable steps” may differ depending on the Recipient’s size and scope of services. HHS advised that Recipients, in designing an LEP program, should conduct an individualized assessment balancing four factors, including: (i) the number or proportion of LEP persons eligible to be served or likely to be encountered by the Recipient; (ii) the frequency with which LEP individuals come into contact with the Recipient’s program; (iii) the nature and importance of the program, activity or service provided by the Recipient to its beneficiaries; and (iv) the resources available to the Recipient and the costs of interpreting and translation services.

Based on the Recipient’s analysis, the Recipient should then design an LEP plan based on five recommended steps, including: (i) identifying LEP individuals who may need assistance; (ii) identifying language assistance measures; (iii) training staff; (iv) providing notice to LEP persons; and (v) monitoring and updating the LEP plan.

A Recipient’s LEP plan likely will include translating vital documents and providing either on-site interpreters or telephone interpreter services, or using shared interpreting services with other Recipients. Recipients may take other reasonable steps depending on the emergent or non-emergent needs of the LEP individual, such as hiring bilingual staff who are competent in the skills required for medical translation, hiring staff interpreters, or contracting with outside public or private agencies that provide interpreter services. HHS’s guidance provides detailed examples of the mix of services that a Recipient should consider and implement. HHS’s guidance also establishes a “safe harbor” that Recipients may elect to follow when determining whether vital documents must be translated into other languages. Compliance with the safe harbor will be strong evidence that the Recipient has satisfied its written translation obligations.

In addition to reviewing HHS guidance documents, Recipients may contact HHS’s Office for Civil Rights for technical assistance in establishing a reasonable LEP plan.

III. California Law – Dymally-Alatorre Bilingual Services Act.

The California legislature enacted the California's Dymally-Alatorre Bilingual Services Act (Govt. Code 7290 *et seq.*) in order to ensure that California residents would appropriately receive services from public agencies regardless of the person's English language skills. California Government Code section 7291 recites this legislative intent as follows:

"The Legislature hereby finds and declares that the effective maintenance and development of a free and democratic society depends on the right and ability of its citizens and residents to communicate with their government and the right and ability of the government to communicate with them.

The Legislature further finds and declares that substantial numbers of persons who live, work and pay taxes in this state are unable, either because they do not speak or write English at all, or because their primary language is other than English, effectively to communicate with their government. The Legislature further finds and declares that state and local agency employees frequently are unable to communicate with persons requiring their services because of this language barrier. As a consequence, substantial numbers of persons presently are being denied rights and benefits to which they would otherwise be entitled.

It is the intention of the Legislature in enacting this chapter to provide for effective communication between all levels of government in this state and the people of this state who are precluded from utilizing public services because of language barriers."

The Act generally requires state and local public agencies to provide interpreter and written document translation services in a manner that will ensure that LEP individuals have access to important government services. Agencies may employ bilingual staff, and translate documents into additional languages representing the clientele served by the agency. Public agencies also must conduct a needs assessment survey every two years documenting the items listed in Government Code section 7299.4, and develop an implementation plan every year that documents compliance with the Act. You may access a copy of this law at the following url: <http://www.spb.ca.gov/bilingual/dymallyact.htm>

FACULTY LIST

Conference Course Directors

A. Dimitrios Colevas, MD

Stanford University School of Medicine

David Gandara, MD

University of California Davis Comprehensive Cancer Center

Margaret Tempero, MD

University of California, San Francisco

Panel Chairs

Jennifer Caswell- Jin, MD

Breast Cancer Tumor Board Cases

Stanford University

Brian Jonas, MD

Hematologic Malignancies Tumor Board Cases

University of California Davis

A. Dimitrios Colevas, MD

Head & Neck Cancer Tumor Board Cases

Stanford University

Robert Canter, MD

Sarcoma Tumor Board Board Cases

University of California Davis

Collin Blakely, MD

Thoracic Cancer Tumor Board Cases

University of California, San Francisco

Charmalambos Andreadis, MD

Lymphoma Tumor Board Cases

University of California, San Francisco

Adil Daud, MD

Non-Melanoma Cutaneous Cancer Board Cases

University of California, San Francisco

Edward Kim, MD

Gastrointestinal Cancers Tumor Board Cases

University of California Davis

Sumit Shah, MD

Genitourinary Cancers Tumor Board Cases

Stanford University

Panelists

Ranjana Advani, MD

Lymphoma Tumor Board Cases

Stanford University

Wei Ai, MD

Lymphoma Tumor Board Cases

University of California, San Francisco

Alain Algazi, MD

Head & Neck Cancer Tumor Board Cases

University of California, San Francisco

Ebaa Al-Obeidi, MD

Gastrointestinal Cancers Tumor Board Cases

University of California Davis

Charmalambos Andreadis, MD

Lymphoma Tumor Board Cases

University of California, San Francisco

Mili Arora, MD

Breast Cancer Tumor Board Cases

University of California Davis

Sarah Arron, MD

Non-Melanoma Cutaneous Cancer Board Cases

University of California, San Francisco

Fred Baik, MD

Head & Neck Cancer Tumor Board Cases

Stanford University

Beth Beadle, MD

Head & Neck Cancer Tumor Board Cases

Stanford University

Deepti Behl, MD

Sarcoma Tumor Board Board Cases

Sutter Health

Caroline Behler, MD

Hematologic Malignancies Tumor Board Cases

Pacific Hematology Oncology Associates

Colin Bergstrom

Breast Cancer Tumor Board Cases

Stanford University

Andrew Birkeland, MD

Head & Neck Cancer Tumor Board Cases

University of California, San Francisco

Jeffrey Bien, MD

Sarcoma Tumor Board Board Cases

Kaiser Permanente

Collin Blakely, MD

Thoracic Cancer Tumor Board Cases

University of California, San Francisco

Lisa Brown, MD

Thoracic Cancer Tumor Board Cases

University of California, Davis

Nam Bui, MD

Sarcoma Tumor Board Board Cases

Stanford University

Robert Canter, MD

Sarcoma Tumor Board Board Cases

University of California Davis

Janai Carr-Ascher, MD

Sarcoma Tumor Board Board Cases

University of California Davis

Jennifer Caswell- Jin, MD

Breast Cancer Tumor Board Cases

Stanford University

Panelists (continued)

Anne Chang, MD
Non-Melanoma Cutaneous Cancer Board Cases
Stanford University

Gigi Chen, MD
Thoracic Cancer Tumor Board Cases
John Muir Health

Helen Chew, MD
Breast Cancer Tumor Board Cases
University of California Davis

Alex Chin, MD
Thoracic Cancer Tumor Board Cases
Stanford University

Aditi Choudhry, MD
Genitourinary Cancers Tumor Board Cases
John Muir Health

Jincy Clement, MD
Breast Cancer Tumor Board Cases
First California Physician Partners

A. Dimitrios Colevas, MD
Head & Neck Cancer Tumor Board Cases
Stanford University

Meryl Colton, MD
Lymphoma Tumor Board Cases
University of California, San Francisco

Megan Daly, MD
Thoracic Cancer Tumor Board Cases
University of California, Davis

Millie Das, MD
Thoracic Cancer Tumor Board Cases
Stanford University

Daniel James DeLitto, MD
Sarcoma Tumor Board Board Cases
Stanford University

Vasu Divi, MD
Non-Melanoma Cutaneous Cancer Board Cases
Stanford University

Kate Doyle, MD
Sarcoma Tumor Board Board Cases
University of California Davis

Cheryl Ewing, MD
Breast Cancer Tumor Board Cases
University of California, San Francisco

Felix Feng, MD
Genitourinary Cancers Tumor Board Cases
University of California, San Francisco

Mary Feng, MD
Gastrointestinal Cancers Tumor Board Cases
University of California, San Francisco

Pauline Funchain
Non-Melanoma Cutaneous Cancer Board Cases
Stanford University

David Gandara, MD
Thoracic Cancer Tumor Board Cases
University of California, Davis
Comprehensive Cancer Center

Michael Glover, MD
Genitourinary Cancers Tumor Board Cases
Stanford University

Lukas Kas Vitzthum, MD
Gastrointestinal Cancers Tumor Board Cases
Stanford University

Adil Daud, MD
Non-Melanoma Cutaneous Cancer Board Cases
University of California, San Francisco

Roy Grekin
Non-Melanoma Cutaneous Cancer Board Cases
University of California, San Francisco

Panelists (continued)

Matthew Gubens, MD
Thoracic Cancer Tumor Board Cases
University of California, San Francisco

Neel Gupta, MD
Lymphoma Tumor Board Cases
Stanford University

Patrick Ha, MD
Head & Neck Cancer Tumor Board Cases
University of California, San Francisco

Patrick Ha
Non-Melanoma Cutaneous Cancer Board Cases
University of California, San Francisco

Alexandra Haugh, MD
Non-Melanoma Cutaneous Cancer Board Cases
University of California, San Francisco

Rasmus Hoeg, MD
Hematologic Malignancies Tumor Board Cases
University of California Davis

Richard Hoppe, MD
Lymphoma Tumor Board Cases
Stanford University

Jewel Johl, MD
Gastrointestinal Cancers Tumor Board Cases
John Muir Health

Brian Jonas, MD,
Hematologic Malignancies Tumor Board Cases
University of California Davis

Jed Katzel, MD
Head & Neck Cancer Tumor Board Cases
Kaiser Permanente

Saad Khan, MD
Head & Neck Cancer Tumor Board Cases
Stanford University

Edward Kim, MD
Gastrointestinal Cancers Tumor Board Cases
University of California Davis

Krishna Komanduri, MD
Hematologic Malignancies Tumor Board Cases
University of California, San Francisco

Vadim Koshkin, MD
Genitourinary Cancers Tumor Board Cases
University of California, San Francisco

Lisa Law, MD
Lymphoma Tumor Board Cases
Kaiser Permanente

Howard Lee, MD
Thoracic Cancer Tumor Board Cases
University of California, San Francisco

Steven Lee, MD
Gastrointestinal Cancers Tumor Board Cases
Kaiser Permanente

Natalie Lui, MD
Thoracic Cancer Tumor Board Cases
Stanford University

Panelists (continued)

Ajay Maker, MD

Gastrointestinal Cancers Tumor Board Cases

University of California, San Francisco

Tom Martin, MD

Hematologic Malignancies Tumor Board Cases

University of California, San Francisco

Lekha Mikkilileni, MD

Hematologic Malignancies Tumor Board Cases

Stanford University

Nicholas Mitsiades, MD

Genitourinary Cancers Tumor Board Cases

University of California Davis

Everett Moding, MD

Sarcoma Tumor Board Board Cases

Stanford University

Alfonzo Molina, MD

Head & Neck Cancer Tumor Board Cases

Stanford University

Varun Monga, MD

Sarcoma Tumor Board Board Cases

University of California, San Francisco

Arta Monjazebe, MD, PhD

Gastrointestinal Cancers Tumor Board Cases

University of California Davis

Claire Mulvey, MD

Thoracic Cancer Tumor Board Cases

University of California, San Francisco

Kim-Son Nguyen, MD

Thoracic Cancer Tumor Board Cases

Palo Alto Medical Foundation

Rebecca Olin, MD

Hematologic Malignancies Tumor Board Cases

University of California, San Francisco

Catherine Park, MD

Breast Cancer Tumor Board Cases

University of California, San Francisco

Shyam Rao, MD

Head & Neck Cancer Tumor Board Cases

University of California, San Francisco

Fauzia Riaz, MD

Breast Cancer Tumor Board Cases

Stanford University

Jonathan Riess, MD

Thoracic Cancer Tumor Board Cases

University of California, Davis

Hope Rugo, MD

Breast Cancer Tumor Board Cases

University of California, San Francisco

Candice Sauder MD

Breast Cancer Tumor Board Cases

University of California Davis

Brian Shulte, MD

Sarcoma Tumor Board Board Cases

University of California, San Francisco

Sumit Shah, MD

Genitourinary Cancers Tumor Board Cases

Stanford University

Shagufta Shaheen, MD

Gastrointestinal Cancers Tumor Board Cases

Stanford University

Panelists (continued)

Mamta Parikh, MD
Genitourinary Cancers Tumor Board Cases
University of California Davis

William Shomali, MD
Hematologic Malignancies Tumor Board Cases
Stanford University

Geoffrey Sonn, MD
Genitourinary Cancers Tumor Board Cases
Stanford University

Michael Spinner, MD
Lymphoma Tumor Board Cases
University of California, San Francisco

Ryan Stevenson, MD
Hematologic Malignancies Tumor Board Cases
Kaiser Permanente

Jennifer Suga, MD
Thoracic Cancer Tumor Board Cases
Kaiser Permanente

Melinda Telli, MD
Breast Cancer Tumor Board Cases
Stanford University

Candice N Thompson, MD
Breast Cancer Tumor Board Cases
Stanford University

Aaron Tsumura, MD
Hematologic Malignancies Tumor Board Cases
University of California Davis

Joseph Tuscano, MD
Lymphoma Tumor Board Cases
University of California, Davis

Richard Valicenti, MD
Genitourinary Cancers Tumor Board Cases
University of California Davis

Heather Wakelee, MD
Thoracic Cancer Tumor Board Cases
Stanford University

Evan Walker, MD
Gastrointestinal Cancers Tumor Board Cases
University of California, San Francisco

Sinai-Yu Wang, MD
Head & Neck Cancer Tumor Board Cases
University of California Davis

Sam Washington, MD
Genitourinary Cancers Tumor Board Cases
University of California, San Francisco

Rosie Wustrack, MD
Sarcoma Tumor Board Board Cases
University of California, San Francisco

Sue Yom, MD
Head & Neck Cancer Tumor Board Cases
University of California, San Francisco

Sue Yom, MD
Thoracic Cancer Tumor Board Cases
University of California, San Francisco

DISCLOSURES

The following faculty speakers, moderators, and planning committee members have disclosed they have no financial interest/arrangement or affiliation with any ineligible companies who have provided products or services relating to their presentation(s) or commercial support for this continuing medical education activity:

Ebaa Al-Obeidi, MD	Michael Glover, MD	Cathy Park, MD
Mili Arora, MD	Roy Grekin	Shyam Rao, MD
Fred Baik, MD	Alexandra Haugh, MD	Fauzia Riaz, MD
Beth Beadle, MD	Rasmus Hoeg, MD	Candice Sauder MD
Caroline Behler, MD	Richard Hoppe, MD	Brian Shulte, MD
Colin Bergstrom	Lukas Kas Vitzthum, MD	Shagufta Shaheen, MD
Lisa Brown, MD	Jed Katzel, MD	Ryan Stevenson, MD
Robert Canter, MD	Krishna Komanduri, MD	Jennifer Suga, MD
Janai Carr-Ascher, MD	Lisa Law, MD, TPMG	Candice N Thompson, MD
Helen Chew, MD	Howard Lee, MD	Aaron Tsumura, MD
Aditi Choudhry, MD	Steven Lee, MD	Joseph Tuscano, MD
Jincy Clement, MD	Ajay Maker, MD	Richard Valicenti, MD
Meryl Colton, MD	Nicholas Mitsiades	Sinai-Yu Wang, MD
Daniel James DeLitto, MD	Everett Moding, MD	Sam Washington, MD
Kate Doyle, MD	Alfonzo Molina, MD	Rosie Wustrack, MD
Cheryl Ewing, MD	Kim-Son Nguyen, MD	

Please see the registration desk to receive a full listing of -faculty speakers who have disclosed a financial relationship with an ineligible company who has provided products or services relating to their presentation(s) or commercial support for this continuing medical education activity. All relevant financial relationships have been mitigated in accordance with the ACCME's Standards for Integrity and Independence.

Ranjana Advani, MD	Vasu Divi, MD	Varun Monga, MD
Wei Ai, MD	Mary Feng, MD	Arta Monjazebe, MD, PhD
Charmalambos Andreadis, MD	Felix Feng, MD	Claire Mulvey, MD
Sarah Arron, MD	Pauline Funchain	Rebecca Olin, MD
Deepti Behl	David Gandara, MD	Mamta Parikh, MD
Andrew Birkeland, MD	Matthew Gubens, MD	Jonathan Riess, MD
Collin Blakely, MD	Neel Gupta, MD	Hope Rugo, MD
Nam Bui, MD	Patrick Ha, MD	Sumit Shah, MD
Jennifer Caswell- Jin, MD	Patrick Ha	William Shomali, MD
Anne Chang, MD	Jewel Johl, MD	Geoffrey Sonn, MD
Gigi Chen, MD	Brian Jonas, MD,	Michael Spinner, MD
Alex Chin, MD	Saad Khan, MD	Heather Wakelee, MD
A. Dimitrios Colevas, MD	Edward Kim, MD	Evan Walker, MD
Megan Daly, MD	Vadim Koshkin, MD	Sue Yom, MD
Millie Das, MD	Natalie Lui, MD	
Adil Daud, MD	Lekha Mikkilileni, MD	

This CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

This activity has been reviewed and approved by members of the UCSF CME Governing Board in accordance with UCSF CME accreditation policies. Office of CME staff, planners, reviewers, and all others in control of content have disclosed no relevant financial relationships.

24th Multidisciplinary Management of Cancers: A Case-Based Approach

COURSE PROGRAM

Friday, March 15, 2024

7:30am	<i>Registration and Continental Breakfast</i>	Silverado Foyer
8:25	Welcome and Opening Remarks	Silverado Ballroom
8:30	Breast Cancer Tumor Board Cases	Jennifer Caswell- Jin, MD Colin Bergstrom Mili Arora, MD Helen Chew, MD Jincy Clement, MD Cheryl Ewing, MD Catherine Park, MD Fauzia Riaz, MD Hope Rugo, MD Candice Sauder, MD Melinda Telli, MD Candice N Thompson, MD
10:30	<i>Break</i>	
11:00	Hematologic Malignancies Tumor Board Cases	Brian Jonas, MD, Aaron Tsumura, MD Caroline Behler, MD Rasmus Hoeg, MD Krishna Komanduri, MD Lekha Mikkilileni, MD Rebecca Olin, MD Ryan Stevenson, MD William Shomali, MD Tom Martin, MD
12:30pm	<i>Lunch</i>	
1:30	Head & Neck Cancer Board Cases	A. Dimitrios Colevas, MD Alfonzo Molina, MD Alain Algazi, MD Fred Baik, MD Beth Beadle, MD Andrew Birkeland, MD Patrick Ha, MD Jed Katzel, MD Saad Khan, MD Shyam Rao, MD Sinai-Yu Wang, MD Sue Yom, MD
3:00	<i>Break</i>	

3:30	Sarcoma Board Cases	Robert Canter, MD Katherine Doyle, MD Janai Carr-Ascher, MD Deepti Behl, MD Everett Moding, MD Varun Monga, MD Brian Shulte, MD Rosie Wustrack, MD Daniel James DeLitto, MD Nam Bui, MD Jeffrey Bien, MD
5:00pm	<i>Adjourn</i>	
5:00 -6:30pm	Welcome Reception	

Saturday, March 16, 2024

8:00am	<i>Continental Breakfast</i>	
8:25	Welcome and Opening Remarks	Silverado Ballroom
8:30	Thoracic Cancer Tumor Board Cases	Collin Blakely, MD Howard Lee, MD Lisa Brown, MD Gigi Chen, MD Alex Chin, MD Megan Daly, MD Millie Das, MD David Gandara, MD Matthew Gubens, MD Natalie Lui, MD Claire Mulvey, MD Kim-Son Nguyen, MD Jonathan Riess, MD Jennifer Suga, MD Heather Wakelee, MD Sue Yom, MD
10:30	<i>Break</i>	
11:00	Lymphoma Tumor Board Cases	Charalambos (Babis) Andreadis, MD Meryl Colton, MD Richard Hoppe, MD Lisa Law, MD, TPMG Neel Gupta, MD Michael Spinner, MD Joseph Tuscano, MD Ranjana Advani, MD Wei Ai, MD
12:30 pm	<i>Lunch</i>	
1:30	Non-Melanoma Cutaneous Cancer Board Cases	Adil Daud, MD Alexandra Haugh, MD Sarah Arron, MD Vasu Divi, MD Anne Chang, MD Patrick Ha, MD Pauline Funchain, MD Roy Grekin, MD

Sunday, March 17, 2024

8:00am	<i>Continental Breakfast</i>	
8:25	Welcome and Opening Remarks	Silverado Ballroom
8:30	Gastrointestinal Cancers Tumor Board Cases	Edward Kim, MD Ebaa Al-Obeidi, MD Mary Feng, MD Jewel Johl, MD Lukas Kas Vitzthum, MD Steven Lee MD Ajay Maker, MD Arta Monjazebe, MD, Shagufta Shaheen, MD Evan Walker, MD
10:30	<i>Break</i>	
11:00	Genitourinary Cancers Tumor Board Cases	Sumit Shah, MD Michael Glover, MD Vadim Koshkin, MD Nicholas Mitsiades, MD Mamta Parikh, MD Geoffrey Sonn, MD Richard Valicenti, MD Samuel Washington, MD Aditi Choudhry, MD Felix Feng, MD
12:30	Adjourn	